Jump to content
×
×
  • Create New...

jameshebrew

Novato
  • Posts

    5
  • Joined

  • Last visited

About jameshebrew

Informações

  • Forma que conheci o xTibia
    Sites de Busca
  • Sou
    OT-Admin
  1. Amongst the total players involved in the development of RNA extraction and purification kits and reagents, majority of the players engaged in the development of RNA extraction and purification kits were established between 1981-2000. During our research, we were able to identify more than 60 developers were involved in the development of RNA extraction and purification kits and reagents. The RNA extraction and purification kits market is currently dominated by the presence of small companies. This is followed by the presence of well-established players in this domain. Further, most of the manufacturers of RNA extraction kits are headquartered in North America. Within this region, the US has emerged as the most prominent region, having the highest number of manufacturers. This is followed by the number of stakeholders headquartered in Asia-Pacific, with China and India being the base of operations for seven companies engaged in this domain. As can be observed in the figure, majority of the kits employ spin column technology for RNA extraction and purification. This is followed by the number of kits that employ magnetic beads technologies for the extraction and RNA purification. Further, maximum number of the kits have the ability to extract total RNA, followed by the kits that can extract viral RNA. To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/rna-extraction-and-purification/request-sample.html It is evident from the figure that over 80% of the RNA isolated using RNA extraction and purification kits are used for PCR / RT-PCR applications, whereas 49% isolated RNA are used for blotting applications. It is worth mentioning that close to 50% kits are used to isolate RNA for SARS-CoV-2 analysis. With the increasing adoption of molecular diagnostics and introduction of novel and advanced RNA extraction and purification techniques, the RNA isolation and purification market is anticipated to witness steady growth in the coming years. For additional details, please visit https://www.rootsanalysis.com/reports/rna-extraction-and-purification.html You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
  2. In recent years, the potential of cell invasion and migration assays with respect to discovery, diagnosis and screening of diseases has been widely recognized, which has further presented lucrative opportunities for players offering such products. London Roots Analysis has announced the addition of the “Cell Invasion and Migration Assays Market, 2022–2035” report to its list of offerings. Owing to several advantages offered by cell invasion and migration assays in analyzing and quantifying cellular mechanisms, industry stakeholders have undertaken numerous R&D initiatives focused on exploiting the use of such assays to expediate discovery timelines and optimize the total development cost. Considering the various advantages offered by these cell-based assays, researchers across the globe have undertaken several initiatives to use these platforms for the diagnosis of a myriad of disease indications. The advancements in various technologies have propelled life science companies to use these assays in the drug discovery process, to enable the identification of potential lead candidates. To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/cell-invasion-and-migration-assays-market/request-sample.html Key Market Insights Presently, more than 80% of the total assay providers are based in North America This segment of the industry is dominated by the presence of companies that were established pre-2000 (64%), followed by firms established during 2000-2010 (27%). In addition, most of the players engaged in this domain are small firms (less than 100 employees), representing over 45% of the total assay providers. Currently, over 80 cell invasion and migration assays are available in the market It is worth noting that most of the cell invasion and migration assays are currently being used for tumor studies (89%), followed by those employed for screening purposes (79%). Further, most of the assays are being developed for adherent cell cultures (48%), followed by those being manufactured for both adherent and suspension cell cultures (40%). 55% players claim to be capable of offering both cell invasion as well as cell migration assays 64% of the cell invasion and migration assays can be stored under frozen temperature (-18°C to -40°C), followed by those stored under refrigerated conditions (+1°C to +18°C) (36%). Further, it is worth noting that most of the cell invasion and migration assays are being used to conduct 100 tests (37%). This was followed by assays being developed to conduct 12 (35%) and 96 tests (23%). Over 650 articles focused on cell invasion and migration assays have been published, since 2021 Majority of the scientific literature published in this domain was focused on research (96%), followed by review articles (4%). It is worth mentioning that articles related to cell invasion and migration assays have been affiliated by over 300 universities. Patents filed / granted for cell invasion and migration assays have increased at a CAGR of more than 45%, since 2017 Of the total, around 55% of the patents were applications, followed by those that have been granted approval (45%). Around 63% of these intellectual property documents were filed / granted in North America; with the maximum number of patents having been filed in the US, since 2017. More than 690 grants have been awarded to support the ongoing research efforts in this domain Several non-profit organizations have extended financial support to aid the research related to cell invasion and migration assays. It is worth mentioning that NCI emerged as the most prominent non-profit organization, having awarded over 60% of grants, followed by NIGMS (17%). North America and Asia-Pacific are anticipated to capture over 70% of the market share, in 2035 In terms of type of assay, the current market is driven by cell invasion assays (56%); this trend is unlikely to change in the foreseen future. Further, based on application area, assays intended for tumor studies are likely to have the maximum revenue generation potential (64%) in the overall market in 2035. For additional details, please visit https://www.rootsanalysis.com/reports/cell-invasion-and-migration-assays-market.html You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
  3. Owing to the recent approval of therapies, such as Elzonris®, Pluvicto®, there has been a substantial increase in the R&D activity to evaluate the use of novel antibody therapy candidates for the treatment of a variety of disease indications Roots Analysis has announced the addition of “Novel Antibody Therapies Market, 2022-2035” report to its list of offerings. Antibodies are the key components of immune system that bind to specific markers on cells or tissues, thereby offering first line of defense against multiple disorders. This has opened a new target space for the development of antibody therapeutics and techniques, facilitating tools to uniquely distinct malignantly transformed cells from regular cells. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/novel-antibody-therapies-market/request-sample.html Key Market Insights Presently, 140+ novel antibody therapies have been marketed / are being evaluated across different phases of development for the treatment of various disease indications Till date, five novel antibody therapies have been marketed and close to 80% of the pipeline candidates are under clinical evaluation. It is worth mentioning that most of the drug candidates are immunotoxins (34%), followed by immunocytokines (32.5%). Majority of these therapies are under clinical trials for the treatment of lymphoma (22) followed by solid tumors (19) and leukemia (18). Around 60 industry and non-industry players are engaged in the development of novel antibody therapies, globally North America has emerged as the hub, featuring the presence of approximately 60% developers. The market is currently dominated by the presence of small players (27%). Interestingly, 16% of the players are big pharma companies engaged in the development of such therapeutics for multiple target indications. More than 550 clinical trials have been registered for the evaluation of novel antibody therapies, worldwide The clinical research activity, in terms of number of trials registered, is reported to have increased at a steady CAGR of 8%, during the period 2016-2021. Of the total number of trials registered, close to 60% have already been completed, while 25% of the studies are actively recruiting participants. Close to 600 articles related to novel antibody therapies, have been published in reputed scientific journals, since 2017 More than 95% of the articles focused on novel antibody therapies were published post-2019. Popular journals that have published multiple articles include Cancer, Frontiers in Immunology, International Journal of Molecular Sciences and Scientific Reports. Over 4,600 patents have been filed / granted related to novel antibody therapies, since 2017 More than 1,150 patents were filed / granted in 2021. Further, around 56% of the patents were filed in North America. It is worth highlighting that majority of the patents were granted / filed by prominent industry / non-Industry players, such as Novartis, Hoffmann la Roche, Immatics Biotechnologies and Pfizer. Partnership activity in this field has increased at a CAGR of over 55%, since 2018 Around 50% of the reported deals were established post-2021, indicating a recent rise in the interest of players engaged in this domain. It is worth highlighting that majority of the agreements were supply agreements (19%), followed by product development and commercialization agreements (15%). North America is anticipated to capture larger share of the phase III novel antibody therapies market by 2035 Around 40% of the market revenues are likely to be generated from the sales of drug candidates being evaluated in phase III for bladder cancer. Further, therapies designed for intravenous route of administration are expected to occupy close to 70% of the overall market. For additional details, please visit https://www.rootsanalysis.com/reports/novel-antibody-therapies-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
  4. Given the recent shift from the one-size-fits-all model to a more personalized mode of treatment, there has been a growing interest in identification and adoption of novel techniques. It is estimated that there are around 20,000 genes present in the human body, all of which interact with the nutrients in the food, either directly or indirectly. Since the introduction of a gene sequencing method by Frederick Sanger in 1977, the field of genomic data collection and analysis has evolved significantly. Advances in DNA sequencing technologies have enabled significant developments in a variety of healthcare-focused research fields, such as precision medicine and diagnostics. Further, the success of the Human Genome Project, which mapped the whole human DNA, has paved a path for the novel concept of nutrigenomics, the science studying the relationship between human genome, nutrition and health. One of the key objectives of the report was to evaluate the current opportunity and future potential associated with the nutrigenomics market, over the coming 13 years. We have provided informed estimates of the likely evolution of the nutrigenomics market in the short to mid-term and long term, for the period 2022-2035. To request a sample copy / brochure of this report, please visit link https://www.rootsanalysis.com/reports/nutrigenomics-market/request-sample.html Presently, extensive studies are being conducted to understand the interaction between nutrients and gene expression at the molecular level to determine effect of a specific nutrient and dietary regime on the human health. Although the field of nutritional genomics is still in a nascent stage, it is a moving at a very fast-pace and is believed to have the potential to lay the foundation for personalized nutrition offerings. Further, the growing interest in nutrigenomics is supported by the rising awareness about the influence of diet on human health and its potential with respect to minimizing the risk of various diet-related diseases, including diabetes, cardiovascular disorders, chronic respiratory diseases and oncological disorders. It is worth mentioning that there are several companies that provide nutrigenomic test offerings directly to consumer, through availability of online genetic test kits and at-home sample collection facilities. Moreover, this field is evolving continuously, as researchers and industry players alike aim to enhance the existing offerings. This field is evolving continuously, as researchers and industry players alike aim to enhance the existing offerings. In this context, in the past 3 years, over 135 nutrigenomics focused research articles have been published, highlighting the active initiatives of researchers to illustrate the effect of nutrition on regulation of gene expression. At present, there are some ethical and regulatory challenges associated with nutrigenomics, including the potential misuse of personal data, as well as uncertainty related to genetic phenotypic predispositions, for conditions where no proven treatment exists. However, the benefits offered by nutrigenomics outweigh the uncertainty associated with its adoption. Considering the growing focus on personalized diets and active initiatives being undertaken by players in this domain, we are led to believe that the opportunity for stakeholders in this niche, but upcoming, industry is likely to grow at a commendable pace in the foreseen future. For additional details, please visit link https://www.rootsanalysis.com/reports/nutrigenomics-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
  5. Rise in clinical research activity for genetically modified therapies has resulted in the increase in demand for vectors, offering lucrative opportunities to players having capabilities for in-house and contract manufacturing of various types of vectors. Roots Analysis has announced the addition of “Viral Vector, Non-Viral Vector and Gene Therapy Manufacturing Market (5th Edition), 2022-2035” report to its list of offerings. The viral vector manufacturing and non-viral vector manufacturing landscape features a mix of industry players (well-established companies, mid-sized firms and start-ups / small companies), as well as several academic institutes. Over the past few years, cell and gene therapies have gained significant popularity owing to their therapeutic potential. In fact, more than 20 genetically modified therapies have already been approved, which has resulted in the increase in demand for vectors, which have proven to be highly efficient for the delivery of genetic material to the targeted area. In order to cater to the growing demand, several companies are offering diverse range of services for vector and gene therapy manufacturing. To request a sample copy / brochure of this report, please visit link https://www.rootsanalysis.com/reports/274/request-sample.html Key Market Insights More than 140 stakeholders claim to manufacture viral and non-viral vectors The market is currently dominated by the presence of various mid-sized industry players (50%); of these 57% of players are contract manufacturers, whereas 22% of players are in-house manufacturers. Over the time, several advancements have been made for the development of vector based technological platforms Majority (37%) of the available technologies are currently used in vector manufacturing followed by those available for manufacturing of cell and gene therapies (16%). Further, 53% of the vector-based technologies are dedicated for the development and manufacturing of adenoviral vectors. More than 295 partnerships were established between different stakeholders during the last decade Close to 55% partnerships have been reported post 2018, wherein, maximum partnerships were recorded in year 2022 (till May). Further, maximum partnerships were related to manufacturing (23%) followed by licensing agreement (20%) and product development agreement (15%). Close to 120 expansion activities have been recorded till 2022, growing at a CAGR of 10% Majority of the expansions in this domain were related to the establishment of new facility (39%) followed by facility expansion (12%). The installed vector manufacturing capacity is estimated to be ~186,150 L Majority (70%) of total installed capacity is currently available for clinical / commercial stage manufacturing of viral vectors. Further, players headquartered in North America (56%) have the highest installed capacity, across the globe. Till 2035, the annual demand for vectors is expected to grow at an annualized rate of 11% Currently, North America and Europe contribute to more than 70% of the demand for viral and non-viral vectors. By 2035, the demand, in terms of number of patients in clinical and commercial stage, demand for vectors, is projected to be ~ 400 thousand patients. The market is anticipated to grow at a significant rate, during the period 2022-2035 The majority share of service revenues is anticipated to come from vector manufacturing projects focused on oncological disorders (51%). By 2035, Europe is likely to capture the major share (42%) of the market followed by North America (30%) and Asia-Pacific (23%). For additional details, please visit link https://www.rootsanalysis.com/reports/view_document/viral-vectors-non-viral-vectors-and-gene-therapy-manufacturing-market-/274.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
  • Recently Browsing   0 members

    • No registered users viewing this page.